A Blood Biomarker-guided Precision Medicine Approach for Individualized Neurodegenerative Disease Risk Reduction and Treatment: The Future of Preventive Neurology? (P7-3.016)
Explore the utility of blood-based biomarkers as outcome measures for n-of-1 neurodegenerative disease (NDD) early intervention trials.
Authors
- Beth A. Lewis (ORCID: https://orcid.org/0000-0002-6034-568X)
- Richard Isaacson (ORCID: https://orcid.org/0000-0002-0949-6204)
- Praveen Parthasarathy (ORCID: https://orcid.org/0000-0002-5910-9452)
- Diana Saville
- Nicholas Clute-Reinig
- Philip Sisser
- Alon Seifan (ORCID: https://orcid.org/0000-0001-6470-3600)
- Michael John McCullough (ORCID: https://orcid.org/0000-0001-7829-4684)
- Jessica P. Lakis
- Hollie Hristov
- Maia Mossé
- Kellyann Niotis
- Corey Saperia (ORCID: https://orcid.org/0009-0003-2598-1482)
- Helena Colvee
- Christopher Janney
- S. Murray
- Shannon Helfman
- Danny Angerbauer
- Juan Melendez-Herencia
- Jannatul Dishary
- Audree Rumberger
- John Westine
Institutions
- University of Miami (US)
- Renaissance University (NG)
- Institute for Neurodegenerative Disorders (US)
- Brain (Germany) (DE)
- Atria (NL)
- MARS Memory-Health Network (US)
- Stony Brook University (US)
- Florida Atlantic University (US)
- Stanford University (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208443
- Citations
- 3
- Primary Topic
- Health, Environment, Cognitive Aging
- Type
- article
- Field-Weighted Citation Impact
- 3.60